CJC-1295 and Ipamorelin represent two mechanistically distinct growth hormone secretagogues studied in preclinical and early clinical research contexts.
Growth hormone (GH) secretagogues are compounds that stimulate the release of endogenous GH from the pituitary gland. Two of the most studied compounds in this class are CJC-1295, a synthetic analog of growth hormone-releasing hormone (GHRH), and Ipamorelin, a selective GH secretagogue and ghrelin mimetic. Research interest in these compounds relates to their use as tools for studying GH physiology, metabolic regulation, and tissue composition.
CJC-1295 is a 29-amino acid GHRH analog modified with a drug affinity complex (DAC) technology, which binds to albumin and dramatically extends its plasma half-life compared to native GHRH. In clinical pharmacology studies, CJC-1295 produced sustained elevation of GH and IGF-1 levels over a 6-day period following a single injection. Its extended action profile makes it a useful tool for studying sustained GH secretion patterns.
Ipamorelin is a pentapeptide and selective agonist of the GH secretagogue receptor (GHSR-1a). Unlike other GH secretagogues such as GHRP-6, Ipamorelin demonstrates high selectivity for GH release with minimal effect on cortisol or prolactin secretion in preclinical studies. This selectivity has made it a preferred research compound for studying GH axis physiology without confounding hormonal changes.
For in-vitro research use only. Not for human or veterinary use.